Stay updated on Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.

Latest updates to the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe webpage has been updated to include new results and metrics related to the efficacy and safety of a treatment for psoriatic arthritis, including specific participant outcomes and assessment scores. Notably, the location of the study has changed from Szarvas, Hungary to Hódmezővásárhely, Hungary.SummaryDifference100%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has removed a notice about heavy traffic affecting certain services and products, as well as a message indicating that no results were posted. Additionally, a new message stating 'Results Submitted' has been added.SummaryDifference1%
- Check100 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.